Prevention & lipidsRandomised controlled trial
Plasma reduction of apolipoprotein C-III with olezarsen leads to significant reductions in postprandial triglyceride levels: results from a randomized trial
- Randomised controlled trial
- double-blind
- placebo-controlled
Authors' conclusion
Olezarsen significantly reduces both fasting and postprandial triglyceride levels
Study context
- Population
- Patients with fasting TG ≥4 mmol/L
- Participants
- 28 patients
- Comparison
- Olezarsen vs placebo
- Olezarsenn = 19
- Placebon = 9reference
- Primary endpoint
- Postprandial TG (AUC) and fasting TG
- Follow-up
- 7 weeks
Primary result
Postprandial TG AUC
Placebo-adjusted reduction
50.1%
95% CI −68.3 to −31.8%
P < 0.0001
As reported in the abstract
Further findings
| Outcome | Estimate | P value |
|---|---|---|
| Fasting TG · 7 weeks | placebo adjusted reduction 59.3% (CI −77.3 to −41.2%) | P < 0.0001 |
| Incremental AUC (iAUC) · 7 weeks | reduction vs baseline 30.3% (95% CI −56.2 to −4.3%) | P = 0.026 |
Incremental AUC (iAUC) · 7 weeks
- Placebo-adjusted iAUC remained unchanged
Patients reaching any TG ≥10 mmol/L
- Decreased from 47% to 5% after olezarsen; reduction
- 96.6%
- p<0.0001
Original publication
Plasma reduction of apolipoprotein C-III with olezarsen leads to significant reductions in postprandial triglyceride levels: results from a randomized trial. Eur J Prev Cardiol. Published 30 July 2025. doi:10.1093/eurjpc/zwaf478
Summarised from the published abstract; every number is checked against it